代謝機能障害関連脂肪肝炎（MASH）治療の世界市場レポート 2025年

代謝機能障害関連脂肪肝炎（MASH）治療市場規模は、今後数年で飛躍的な成長が見込まれます。2029年には年間平均成長率（CAGR）29.8％で73億8,000万米ドルに成長します。予測期間中に予想される成長の原動力は、肥満および肥満関連疾患の割合の上昇、早期介入、償還制度の改善、保険適用範囲の拡大、肝疾患に対する意識の高まりです。この期間を形成すると予想される主な動向には、技術の進歩、パイプラインにおける新たな治療法の開発、戦略的提携や共同研究、個別化医療、精密治療、臨床試験や研究への投資の増加などが含まれます。

肥満の蔓延が今後の代謝機能障害関連脂肪肝炎（MASH）治療市場の拡大を牽引すると予想されます。肥満とは、体脂肪が過剰に蓄積した状態を指し、健康全般に害を及ぼす可能性があり、通常、体格指数（BMI）30以上で定義されます。肥満の世界の増加は主に、座りがちなライフスタイル、食生活の乱れ、代謝リスクなどの要因に起因しています。肥満症におけるMASH治療は、生活習慣の改善と標的治療の両方を通じて、インスリン抵抗性と闘い、肝脂肪を減らし、代謝の健康を高めることを目的としています。例えば、2023年3月に発表されたスイスを拠点とする世界の循環器団体である世界心臓財団の報告書によると、世界の成人および小児の約23億人が肥満または過体重であり、この数字は進行中の肥満傾向を反映して、2025年までに27億人に増加すると予測されています。その結果、肥満率の上昇がMASH治療市場の成長を促進しています。

代謝機能障害関連脂肪肝炎（MASH）治療市場の主要企業は、肝線維症の解決策を含む革新的製品の開発に注力しています。これらの治療は、生活習慣の改善、抗ウイルス薬、新たな抗線維化療法を中心に、肝障害の根本原因に対処することを目的としています。目標は、線維化の進行を予防し、逆転させる可能性を持たせ、肝機能を高めることです。例えば、2024年3月、米国のバイオ製薬会社マドリガル・ファーマシューティカルズは、レズディフラ（レスメチロム）のFDA承認を取得しました。これは中等度から重度の肝線維化を伴うMASHに対する初めての治療薬です。日1錠の経口剤であるレズディフラは、第3相臨床試験において、線維症を悪化させることなくMASHを解消し、肝線維症を改善する有効性を示しました。この画期的な新薬は、肝生検に代わる非侵襲的な治療法を提供し、脂肪肝疾患管理における患者のアクセスと治療成績を大幅に改善します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界代謝機能障害関連脂肪肝炎（MASH）治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の代謝機能障害関連脂肪肝炎（MASH）治療市場：成長率分析
• 世界の代謝機能障害関連脂肪肝炎（MASH）治療市場の実績：規模と成長, 2019-2024
• 世界の代謝機能障害関連脂肪肝炎（MASH）治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界代謝機能障害関連脂肪肝炎（MASH）治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の代謝機能障害関連脂肪肝炎（MASH）治療市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬物別
• セラピー別
• 世界の代謝機能障害関連脂肪肝炎（MASH）治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• ホームケア
• その他のエンドユーザー
• 世界の代謝機能障害関連脂肪肝炎（MASH）治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の代謝機能障害関連脂肪肝炎（MASH）治療市場、薬剤別、タイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗線維化剤
• 抗糖尿病薬
• 脂質低下剤
• ビタミンE
• オベチコール酸（OCA）
• GLP-1作動薬
• その他の薬剤（抗炎症薬）
• 世界の代謝機能障害関連脂肪肝炎（MASH）治療市場、治療法別、タイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 薬物療法
• ライフスタイルの変更（食生活の変更、運動）
• 肥満手術
• 肝臓移植

第7章 地域別・国別分析

• 世界の代謝機能障害関連脂肪肝炎（MASH）治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の代謝機能障害関連脂肪肝炎（MASH）治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 代謝機能障害関連脂肪肝炎（MASH）治療市場：競合情勢
• 代謝機能障害関連脂肪肝炎（MASH）治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Eli Lilly and Company
• Gilead Sciences Inc.
• Boehringer Ingelheim International GmbH
• Novo Nordisk A/S
• Apollo Health and Lifestyle Limited
• Jenny Craig
• Celerion
• Nutrisystem
• Madrigal Pharmaceuticals
• Anoos Clinic
• 31.13. Biosynth
• 31.14. DiogenX
• 31.15. Galectin Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 代謝機能障害関連脂肪肝炎（MASH）治療市場2029：新たな機会を提供する国
• 代謝機能障害関連脂肪肝炎（MASH）治療市場2029：新たな機会を提供するセグメント
• 代謝機能障害関連脂肪肝炎（MASH）治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Treatment for metabolic dysfunction-associated steatohepatitis (MASH) involves both medical and lifestyle approaches that target the inflammation and liver damage caused by fat buildup in the liver, which is linked to metabolic issues such as obesity, diabetes, and insulin resistance. The goal is to improve liver function and metabolic health outcomes.

The primary treatments for MASH include medications and therapies. Drug treatments involve the use of pharmaceutical agents to reduce liver inflammation, fibrosis, and fat accumulation, aiming to enhance liver function and halt disease progression. These treatments are provided to patients through various channels, including hospital pharmacies, online pharmacies, retail pharmacies, and specialty clinics, and can be used in settings such as hospitals, homecare, and others.

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market research report is one of a series of new reports from The Business Research Company that provides metabolic dysfunction-associated steatohepatitis (MASH) treatment market statistics, including metabolic dysfunction-associated steatohepatitis (MASH) treatment industry global market size, regional shares, competitors with metabolic dysfunction-associated steatohepatitis (MASH) treatment market share, detailed metabolic dysfunction-associated steatohepatitis (MASH) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the metabolic dysfunction-associated steatohepatitis (MASH) treatment industry. This metabolic dysfunction-associated steatohepatitis (MASH) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market size has grown exponentially in recent years. It will grow from $2.00 billion in 2024 to $2.60 billion in 2025 at a compound annual growth rate (CAGR) of 30.0%. The growth observed in the historical period can be linked to the increasing prevalence of non-alcoholic steatohepatitis, modern dietary trends that include high consumption of processed foods, sedentary lifestyles, and the rising occurrence of metabolic conditions.

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market size is expected to see exponential growth in the next few years. It will grow to $7.38 billion in 2029 at a compound annual growth rate (CAGR) of 29.8%. The anticipated growth during the forecast period is driven by the rising rates of obesity and obesity-related conditions, early interventions, improved reimbursement mechanisms, expanded insurance coverage, and heightened awareness of liver diseases. Key trends expected to shape this period include advancements in technology, the development of new treatments in the pipeline, strategic partnerships and collaborations, personalized medicine, precision therapeutics, and increased investment in clinical trials and research.

The growing prevalence of obesity is expected to drive the expansion of the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in the future. Obesity is a condition marked by excessive body fat accumulation, which can harm overall health and is usually defined by a body mass index (BMI) of 30 or higher. The global rise in obesity is primarily attributed to factors such as sedentary lifestyles, poor dietary habits, and metabolic risks. MASH treatment in obesity aims to combat insulin resistance, reduce liver fat, and enhance metabolic health through both lifestyle modifications and targeted treatments. For example, a report from the World Heart Foundation, a Switzerland-based global cardiovascular organization, published in March 2023, highlighted that around 2.3 billion adults and children worldwide are obese or overweight, and this figure is expected to increase to 2.7 billion by 2025, reflecting the ongoing obesity trend. Consequently, the rise in obesity rates is propelling the growth of the MASH treatment market.

Major companies in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are focusing on the development of innovative products, including solutions for liver fibrosis. These treatments aim to address the root causes of liver damage, with a focus on lifestyle changes, antiviral medications, and emerging antifibrotic therapies. The goal is to prevent the progression of fibrosis, potentially reversing it, and enhancing liver function. For example, in March 2024, Madrigal Pharmaceuticals, a US-based biopharmaceutical company, received FDA approval for Rezdiffra (resmetirom). This is the first-ever treatment for MASH with moderate to severe liver fibrosis. Rezdiffra, a daily oral tablet, showed effectiveness in resolving MASH without worsening fibrosis and improving liver fibrosis in phase 3 clinical trials. This breakthrough provides a non-invasive alternative to liver biopsies, significantly improving patient access and outcomes in managing fatty liver disease.

In January 2024, Suzhou Ribo Life Science Co., Ltd., a clinical-stage company based in China, and Ribocure Pharmaceuticals AB (Ribo), a clinical-stage biotechnology company from Sweden, announced a $2 billion collaboration with Boehringer Ingelheim. This partnership aims to develop innovative treatments for nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH). The collaboration will combine Ribo's RNAi therapeutic platform with Boehringer Ingelheim's expertise in cardiovascular, renal, and metabolic diseases. The goal is to address the critical need for effective therapies that can halt the progression of NASH and restore liver function. Boehringer Ingelheim, a pharmaceutical company based in Germany, is actively working on treatments for MASH.

Major players in the metabolic dysfunction-associated steatohepatitis (mash) treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lily and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Celerion, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, 89 Bio, Biosynth, DiogenX, Galectin Therapeutics Inc., Galmed Pharmaceuticals, and Hepion Pharmaceuticals.

North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metabolic dysfunction-associated steatohepatitis (MASH) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market consists of revenues earned by entities by providing services such as clinical care services, nutritional counseling, pharmacotherapy management, patient education, and support programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The metabolic dysfunction-associated steatohepatitis (MASH) treatment market also includes sales of antioxidants, antidiabetic drugs, and liver protective supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metabolic dysfunction-associated steatohepatitis (mash) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for metabolic dysfunction-associated steatohepatitis (mash) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metabolic dysfunction-associated steatohepatitis (mash) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: By Drug; By Therapy
• 2) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-User
• 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
• Subsegments:
• 1) By Drug: Antifibrotic Agents; Antidiabetic Drugs; Lipid-Lowering Agents; Vitamin E; Obeticholic Acid (OCA); GLP-1 Agonists; Other Drugs (Anti-Inflammatory Agents)
• 2) By Therapy: Pharmacotherapy; Lifestyle Modifications (Dietary Changes, Exercise); Bariatric Surgery; Liver Transplantation
• Companies Mentioned:Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; Sanofi SA; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Characteristics

3. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Trends And Strategies

4. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Growth Rate Analysis
• 5.4. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Total Addressable Market (TAM)

6. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Segmentation

• 6.1. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• By Drug
• By Therapy
• 6.2. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-User
• 6.3. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• 6.4. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Sub-Segmentation Of By Drug, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antifibrotic Agents
• Antidiabetic Drugs
• Lipid-Lowering Agents
• Vitamin E
• Obeticholic Acid (OCA)
• GLP-1 Agonists
• Other Drugs (Anti-Inflammatory Agents)
• 6.5. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Sub-Segmentation Of By Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmacotherapy
• Lifestyle Modifications (Dietary Changes, Exercise)
• Bariatric Surgery
• Liver Transplantation

7. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Regional And Country Analysis

• 7.1. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 8.1. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 9.1. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 9.2. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 10.1. India Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 11.1. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 11.2. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 12.1. Australia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 13.1. Indonesia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 14.1. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 14.2. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 15.1. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 15.2. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 16.1. UK Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 17.1. Germany Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 18.1. France Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 19.1. Italy Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 20.1. Spain Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 21.1. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 21.2. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 22.1. Russia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 23.1. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 23.2. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 24.1. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 24.2. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 25.1. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 25.2. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 26.1. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 26.2. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 27.1. Brazil Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 28.1. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 28.2. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

• 29.1. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Overview
• 29.2. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Competitive Landscape And Company Profiles

• 30.1. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Competitive Landscape
• 30.2. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Eli Lilly and Company
• 31.3. Gilead Sciences Inc.
• 31.4. Boehringer Ingelheim International GmbH
• 31.5. Novo Nordisk A/S
• 31.6. Apollo Health and Lifestyle Limited
• 31.7. Jenny Craig
• 31.8. Celerion
• 31.9. Nutrisystem
• 31.10. Madrigal Pharmaceuticals
• 31.11. Anoos Clinic
  • 31.12. 89 Bio
• 31.13. Biosynth
• 31.14. DiogenX
• 31.15. Galectin Therapeutics Inc.

32. Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

34. Recent Developments In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market

35. Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer